Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them
Many rheumatic diseases are a model of human pathology disease. These are inflammatory rheumatic diseases, autoinflammatory and autoimmune diseases. Antiphospholipid syndrome (APS) is a model of antibody-induced thrombosis or acquired thrombophilia. In 2023, classification criteria were published, w...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2025-03-01
|
| Series: | Научно-практическая ревматология |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3702 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243269989400576 |
|---|---|
| author | T. M. Reshetnyak |
| author_facet | T. M. Reshetnyak |
| author_sort | T. M. Reshetnyak |
| collection | DOAJ |
| description | Many rheumatic diseases are a model of human pathology disease. These are inflammatory rheumatic diseases, autoinflammatory and autoimmune diseases. Antiphospholipid syndrome (APS) is a model of antibody-induced thrombosis or acquired thrombophilia. In 2023, classification criteria were published, which were developed jointly by the American College of Rheumatology (ACR) and EULAR (European League against Rheumatism) and included a four-stage methodology. This review presents the existing APS classification criteria until 2023 and the 2023 criteria with their explanation.Conclusion. The classification criteria of ACR/EULAR 2023 reflect the multi-organicity and multidisciplinarity of this symptom complex. At the same time, like all classification criteria, they are designed to select homogeneous groups in clinical trials. |
| format | Article |
| id | doaj-art-e518bcf502c1433da4877ad51ac95597 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2025-03-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-e518bcf502c1433da4877ad51ac955972025-08-20T03:59:31ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922025-03-01631122310.47360/1995-4484-2025-12-233049Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on themT. M. Reshetnyak0V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationMany rheumatic diseases are a model of human pathology disease. These are inflammatory rheumatic diseases, autoinflammatory and autoimmune diseases. Antiphospholipid syndrome (APS) is a model of antibody-induced thrombosis or acquired thrombophilia. In 2023, classification criteria were published, which were developed jointly by the American College of Rheumatology (ACR) and EULAR (European League against Rheumatism) and included a four-stage methodology. This review presents the existing APS classification criteria until 2023 and the 2023 criteria with their explanation.Conclusion. The classification criteria of ACR/EULAR 2023 reflect the multi-organicity and multidisciplinarity of this symptom complex. At the same time, like all classification criteria, they are designed to select homogeneous groups in clinical trials.https://rsp.mediar-press.net/rsp/article/view/3702 |
| spellingShingle | T. M. Reshetnyak Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them Научно-практическая ревматология |
| title | Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them |
| title_full | Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them |
| title_fullStr | Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them |
| title_full_unstemmed | Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them |
| title_short | Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them |
| title_sort | classification criteria of antiphospholipid syndrome acr eular 2023 and comments on them |
| url | https://rsp.mediar-press.net/rsp/article/view/3702 |
| work_keys_str_mv | AT tmreshetnyak classificationcriteriaofantiphospholipidsyndromeacreular2023andcommentsonthem |